This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Eargo Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Eargo.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	17.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Eargo: Straining To Be Heard

Aug 30

Eargo jumps 77% following FDA rule on OTC hearing aids

Aug 16

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Aug 08

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

Jul 10

Eargo: I Am Slowly Starting To Listen

May 06

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

Jan 16

Eargo trades high afte hours on strong Q4 revenue, gross systems shipped

Jan 11

Eargo: A Word Of Caution

Dec 15

Eargo beats on revenue

Nov 19

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eargo has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGS:EAR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2023	41	-108	-76	-75	N/A
6/30/2023	41	-141	-76	-75	N/A
3/31/2023	40	-149	-121	-118	N/A
12/31/2022	37	-157	-120	-117	N/A
9/30/2022	34	-159	-145	-142	N/A
6/30/2022	4	-188	-154	-150	N/A
3/31/2022	19	-175	-114	-109	N/A
12/31/2021	32	-158	-103	-98	N/A
9/30/2021	44	-124	-65	-59	N/A
6/30/2021	85	-45	-47	-41	N/A
3/31/2021	79	-32	-31	-26	N/A
12/31/2020	69	-30	-31	-26	N/A
9/30/2020	57	-32	-35	-30	N/A
6/30/2020	47	-44	-40	-36	N/A
3/31/2020	38	-47	-43	-39	N/A
12/31/2019	33	-44	-43	-39	N/A
9/30/2019	30	-42	-41	-37	N/A
12/31/2018	23	-34	-30	-27	N/A
12/31/2017	7	-25	-15	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if EAR's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if EAR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if EAR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if EAR's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if EAR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EAR's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Eargo Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$2.00

Price target decreased to US$2.00

Price target decreased to US$10.50

Eargo, Inc. Withdraws Financial Guidance for the Fiscal Year Ending December 31, 2021

Consensus forecasts updated

Eargo, Inc. Provides Financial Guidance for the Year 2021

Recent updates

Eargo Files Form 15

Eargo, Inc.(NasdaqGS:EAR) dropped from NASDAQ Composite Index

Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings

Eargo, Inc. Announces Chief Financial Officer Changes, Effective from January 5, 2024

Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. (NasdaqGS:EAR) for $13 million.

Patient Square Capital, LP entered into an agreement to acquire remaining 23.8% stake in Eargo, Inc. (NasdaqGS:EAR) for $13 million.

Eargo, Inc. to Report Q1, 2023 Results on May 11, 2023

Nasdaq Confirms Eargo’s Minimum Bid Price Deficiency Is Cured

Hearing Wellness Pioneer Eargo Launches Eargo 7, Its Most Revolutionary Device Yet, at CES

Nasdaq Grants 180 Calendar Days to Eargo, Inc. to Regain Compliance

Less than half of directors are independent

Eargo, Inc. Announces Board Changes

Eargo, Inc. Announces the Appointment of Donald Spence to Its Board of Directors

Eargo, Inc. has completed a Follow-on Equity Offering in the amount of $187.5 million.

Independent Director exercised options to buy US$273k worth of stock.

Eargo Receives Non-Compliance Notice From Nasdaq

Eargo Receives a Non-Compliance Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC

Price target decreased to US$2.00

Third quarter 2022 earnings released: US$1.29 loss per share (vs US$2.02 loss in 3Q 2021)

Eargo, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Eargo: Straining To Be Heard

Eargo jumps 77% following FDA rule on OTC hearing aids

Price target decreased to US$2.00

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Eargo, Inc., Annual General Meeting, Oct 12, 2022

Eargo Non-GAAP EPS of -$0.78 misses by $0.55, revenue of $7.25M misses by $21.05M

Eargo, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Eargo completes $100M senior secured convertible notes issuance

Eargo, Inc.(NasdaqGS:EAR) dropped from Russell 2000 Growth Index

Eargo Receives a Letter from the Nasdaq Stock Market

Eargo Announces Receipt of Nasdaq Non-Compliance Letter

Eargo, Inc. announced delayed 10-Q filing

Eargo, Inc. announced delayed annual 10-K filing

Eargo, Inc. Launches Eargo 6 with Sound Adjust for Effortless Hearing

Eargo: A Binary Play On Hearing Loss

Price target decreased to US$10.50

Eargo Receives Notice from Nasdaq Stating Non Compliance with Listing Rule 5250(C)(1)

Eargo Is A High Risk 'Option' With High Potential

Eargo, Inc. Withdraws Financial Guidance for the Fiscal Year Ending December 31, 2021

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.50 loss per share (vs US$24.11 loss in 2Q 2020)

Eargo, Inc. Provides Financial Guidance for the Year 2021

Independent Director Geoffrey Pardo has left the company

Eargo Launches Eargo 5 Hearing Aid with Sound Match™ Technology

An Intrinsic Calculation For Eargo, Inc. (NASDAQ:EAR) Suggests It's 23% Undervalued

Chief Financial Officer notifies of intention to sell stock

Eargo, Inc.(NasdaqGS:EAR) dropped from Russell 3000E Value Index

Independent Director Juliet Bakker has left the company

Consensus EPS estimates increase to -US$1.00

First quarter 2021 earnings released: US$3.56 loss per share (vs US$33.52 loss in 1Q 2020)

Eargo, Inc. Increases Earnings Guidance for Full Year 2021

Eargo: I Am Slowly Starting To Listen

Independent Director notifies of intention to sell stock

Full year 2020 earnings released: US$3.80 loss per share (vs US$57.82 loss in FY 2019)

Analysts update estimates

Revenue and earnings beat expectations

Full year 2020 earnings released: US$3.80 loss per share (vs US$57.82 loss in FY 2019)

Analysts update estimates

Eargo, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: US$70.31

New 90-day high: US$63.00

What Kind Of Investors Own Most Of Eargo, Inc. (NASDAQ:EAR)?

Eargo trades high afte hours on strong Q4 revenue, gross systems shipped

Eargo: A Word Of Caution

Third quarter 2020 earnings released: US$24.38 loss per share

Eargo, Inc. Provides Earnings Guidance for the Full Year 2020

Eargo beats on revenue